PTC Therapeutics (PTCT) CEO sells 7,371 shares for tax withholding

Rhea-AI Filing Summary

PTC Therapeutics, Inc. reported that Chief Executive Officer Matthew B. Klein automatically sold 7,371 shares of common stock at an average price of $69.36 per share. The sale was made under an irrevocable sell-to-cover election to satisfy tax withholding on the vesting of 17,500 restricted stock units from a February 15, 2025 grant of 70,000 RSUs. Following this tax-related sale, Klein owned 387,082 shares of PTC Therapeutics common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klein Matthew B.

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		S		7,371(1)	D	$69.36	387,082	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 17,500 RSUs from a February 15, 2025 grant of 70,000 RSUs.

	/s/ Avraham S. Adler, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PTC Therapeutics (PTCT) report for Matthew B. Klein?

PTC Therapeutics reported that CEO Matthew B. Klein sold 7,371 shares of common stock. The sale was an automatic sell-to-cover transaction related to tax withholding on the vesting of restricted stock units granted in February 2025.

How many PTC Therapeutics (PTCT) shares did the CEO sell and at what price?

Matthew B. Klein sold 7,371 shares of PTC Therapeutics common stock at an average price of $69.36 per share. This transaction was executed as part of an automatic arrangement to cover tax withholding obligations tied to RSU vesting.

Why were Matthew B. Klein’s PTC Therapeutics (PTCT) shares sold in this Form 4 filing?

The shares were sold to satisfy tax withholding obligations from the vesting of 17,500 restricted stock units. The sale occurred automatically under an irrevocable sell-to-cover election Klein entered into when accepting a February 15, 2025 grant of 70,000 RSUs.

How many PTC Therapeutics (PTCT) shares does the CEO hold after this transaction?

After the tax-related sale, Matthew B. Klein directly owned 387,082 shares of PTC Therapeutics common stock. This post-transaction holding reflects his remaining direct ownership following the automatic sale of 7,371 shares to cover tax withholding obligations.

What equity award is connected to the CEO’s PTC Therapeutics (PTCT) share sale?

The sale is linked to a February 15, 2025 grant of 70,000 restricted stock units to Matthew B. Klein. The 7,371 shares were sold to cover taxes arising from the vesting of 17,500 RSUs from that broader equity award grant.